Quarterly ResultMay 14, 2026, 08:32 AM
Dogwood Therapeutics SP16 IND Approved; Halneuron on Track; $100M Deal
AI Summary
Dogwood Therapeutics announced Q1 2026 financial results, reporting a net loss of $5.0 million, a significant improvement from $12.2 million in Q1 2025. The company achieved key pipeline milestones, including FDA acceptance of the SP16 Investigational New Drug Application for chemotherapy-induced pain and neuropathy, with enrollment starting mid-2026. Its lead candidate, Halneuron, remains on track for top-line Phase 2b results in fall 2026 for chemotherapy-induced neuropathic pain. Additionally, Dogwood secured a worldwide development and commercialization partnership for legacy antiviral assets, potentially valued up to $100 million for the company and its shareholders.
Key Highlights
- Worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100M.
- FDA accepted SP16 Investigational New Drug (IND) Application for chemotherapy-induced pain and neuropathy.
- Halneuron® Phase 2b trial for Chemotherapy Induced Neuropathy on track for top-line results in fall 2026.
- Net loss attributable to common stockholders for Q1 2026 was $5.0 million, down from $12.2 million in Q1 2025.
- Research and development expenses increased to $2.7 million in Q1 2026 from $2.4 million in Q1 2025.
- General and administrative expenses rose to $2.4 million in Q1 2026 from $2.0 million in Q1 2025.
- Cash on hand of $13.2 million provides operational runway into the fourth quarter of 2026.
- Completed financing of up to $26.9 million in January 2026, with $12.5 million gross proceeds received.